PrP meets alpha‐synuclein: Molecular mechanisms and implications for disease

Abstract

The discovery of prions has challenged dogmas and has revolutionized our understanding of protein‐misfolding diseases. The concept of self‐propagation via protein conformational changes, originally discovered for the prion protein (PrP), also applies to other proteins that exhibit similar behavior, such as alpha‐synuclein (aSyn), a central player in Parkinson's disease and in other synucleinopathies. aSyn pathology appears to spread from one cell to another during disease progression, and involves the misfolding and aggregation of aSyn. How the transfer of aSyn between cells occurs is still being studied, but one important hypothesis involves receptor‐mediated transport. Interestingly, recent studies indicate that the cellular prion protein (PrPC) may play a crucial role in this process. PrPC has been shown to act as a receptor/sensor for protein aggregates in different neurodegenerative disorders, including Alzheimer's disease and amyotrophic lateral sclerosis. Here, we provide a comprehensive overview of the current state of knowledge regarding the interaction between aSyn and PrPC and discuss its role in synucleinopathies. We examine the properties of PrP and aSyn, including their structure, function, and aggregation. Additionally, we discuss the current understanding of PrPC's role as a receptor/sensor for aSyn aggregates and identify remaining unanswered questions in this area of research. Ultimately, we posit that exploring the interaction between aSyn and PrPC may offer potential treatment options for synucleinopathies.image

Aging and neurodegeneration: From molecular mechanisms to therapeutic interventions

“…Based on their findings, the same group Gasparotto et al provides a critical discussion of the role of RAGE in Parkinson's disease (Gasparotto et al, 2023). Vieira et al discuss how the prion protein, the culprit in prion diseases, can also play a role in Parkinson's disease by interacting with and acting as a sensor for αsynuclein, thereby leading to alterations in neuronal function (Vieira et al, 2023). Finally, two studies focus more directly on possible therapeutic interventions for neurodegeneration.…”